Who Paid My Doc
Thomas Watters
Nuclear Cardiology San Mateo, CA Medical Doctor
NPI 1508816596 CMS profile 1089131
101 S San Mateo Dr, Suite 303, San Mateo, CA 94401
General payments
$17
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Thomas Watters of San Mateo, CA is reported in the CMS Open Payments database as having received $17 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 2nd percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $17 | 1 |
Beside peers
- Thomas Watters
- Nuclear Cardiology median
- Middle half of Nuclear Cardiology
- National median
In program year 2025, general payments to Thomas Watters were reported at $0. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.
Show as a table
| Year | Thomas Watters | Nuclear Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $552 | $91–$1,768 | $163 |
| 2020 | $17 | $204 | $61–$1,106 | $114 |
| 2021 | $0 | $354 | $99–$886 | $132 |
| 2022 | $0 | $506 | $101–$1,186 | $149 |
| 2023 | $0 | $545 | $148–$1,432 | $160 |
| 2024 | $0 | $484 | $131–$1,430 | $164 |
| 2025 | $0 | $434 | $138–$985 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
87
Drug cost
$11,749
Branded share of claims
17.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Repatha Sureclick Evolocumab | Brand | 15 | $10,954 | |
| Atorvastatin Calcium | Generic | 31 | $365 | |
| Metformin Hcl | Generic | 13 | $164 | |
| Metoprolol Succinate | Generic | 11 | $162 | |
| Amlodipine Besylate | Generic | 17 | $103 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Cardiology in California
Ramin Ebrahimi
Nuclear Cardiology · Los Angeles, CA
Teresa Daniele
Nuclear Cardiology · Fresno, CA
Christopher Oh
Nuclear Cardiology · Salinas, CA
Absalom Hepner
Nuclear Cardiology · Mission Viejo, CA
Howard Lewin
Nuclear Cardiology · Los Angeles, CA
Victor Gabrielian
Nuclear Cardiology · Arcadia, CA
Related records
Nuclear Cardiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.